focus -WSS

focus

author：explore 2025-08-31 20:50:32 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： HIV vaccine remains elusive. Immunologists keep trying new ideas

WSS

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Vir antibody drug aimed at influenza A fails in clinical trial

Vir antibody drug aimed at influenza A fails in clinical trial

Tesla recalling nearly 16,000 of its 2021

Tocagen's brain cancer gene therapy trial continues. Investors worry

DeSantis talks Trump, trans issues and 'what wokeness is'

focus

focus

A Worst CEO gets some much-needed help

hotspot

What does generative AI mean for health care? We asked experts

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

How to save PrEP access — and even expand it

7 more heat

State Dept. review finds Biden bears some blame for Afghanistan failures

Affordable Connectivity Program vital to health care, experts say

Alkermes shareholders re

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Psychedelics group wrestles with new pharma identity

Bird flu: Don't repeat Covid's 'health versus the economy' framing

focus

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Cytokinetics CEO stresses company can launch heart drug on its own

Awakening the world to the whoosh: A patient's crusade

I learned firsthand about improving diversity in clinical trials

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

leisure time

knowledge

hotspot

Wikipedia